DAVID J. PROPPER
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Internal Medicine top 2%
- Venous Thromboembolism Diagnosis and Management
Papers in
- Oncology 36
- Colorectal Cancer Treatments and Studies 9
- Pancreatic and Hepatic Oncology Research 9
- CAR-T cell therapy research 3
- Cancer Treatment and Pharmacology 3
- Hematology 10
- Blood groups and transfusion 7
- Co-authors
- Frances R. Balkwill (6 shared papers)Adrian L. Harris (17 shared papers)Jeremy P. Braybrooke (12 shared papers)Trivadi Sundaram Ganesan (12 shared papers)Kenneth John O'Byrne (10 shared papers)Denis Charles Talbot (9 shared papers)Roger M. Feakins (4 shared papers)Nicola A. Dobbs (4 shared papers)
- Journals
- British Journal of Cancer (13 papers)Annals of Oncology (6 papers)European Journal of Cancer (4 papers)The Lancet Oncology (4 papers)Transplantation (4 papers)
- Partner nations
- United KingdomUnited StatesAustralia
In The Last Decade
DAVID J. PROPPER
82 papers receiving 4.3k citations
DAVID J. PROPPER's Hit Papers
Peers
Comparison fields: 5 of 130
- Oncology 1.8k
- Internal Medicine 227
- Cancer Research 634
- Immunology 817
- Hematology 263
Countries citing papers authored by DAVID J. PROPPER
This map shows the geographic impact of DAVID J. PROPPER's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DAVID J. PROPPER with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DAVID J. PROPPER more than expected).
Fields of papers citing papers by DAVID J. PROPPER
This network shows the impact of papers produced by DAVID J. PROPPER. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DAVID J. PROPPER. The network helps show where DAVID J. PROPPER may publish in the future.
Co-authors
The 25 scholars most cited alongside DAVID J. PROPPER, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 85 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Harnessing cytokines and chemokines for cancer therapy Hit paper breakdown → | 2022 | 774 |
| 2 | Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial Hit paper breakdown → | 2014 | 327 |
| 3 | 2011 | 263 | |
| 4 | 2011 | 208 | |
| 5 | 2001 | 203 | |
| 6 | 2013 | 201 | |
| 7 | 2020 | 182 | |
| 8 | 2008 | 154 | |
| 9 | 2018 | 142 | |
| 10 | 2018 | 130 | |
| 11 | 2018 | 129 | |
| 12 | Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. | 2001 | 119 |
| 13 | 1999 | 115 | |
| 14 | 2018 | 106 | |
| 15 | Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. | 2003 | 93 |
| 16 | 2004 | 75 | |
| 17 | 2017 | 64 | |
| 18 | A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. | 2000 | 57 |
| 19 | 1999 | 56 | |
| 20 | 2009 | 56 |
About DAVID J. PROPPER
DAVID J. PROPPER is a scholar working on Oncology, Hematology, Cancer Research, Immunology and Transplantation, having authored 85 papers that have together received 4.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (9 papers), Pancreatic and Hepatic Oncology Research (9 papers), Blood groups and transfusion (7 papers), Cancer, Hypoxia, and Metabolism (5 papers), Renal Transplantation Outcomes and Treatments (4 papers), T-cell and B-cell Immunology (4 papers), CAR-T cell therapy research (3 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Oncology (1.8k citations), Internal Medicine (227 citations), Cancer Research (634 citations), Immunology (817 citations) and Hematology (263 citations). DAVID J. PROPPER has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Frances R. Balkwill, Adrian L. Harris, Jeremy P. Braybrooke, Trivadi Sundaram Ganesan, Kenneth John O'Byrne, Denis Charles Talbot, Roger M. Feakins, Nicola A. Dobbs, David Walter Fyfe and Camille Ettelaie. Their work appears in journals such as British Journal of Cancer, Annals of Oncology, European Journal of Cancer, The Lancet Oncology and Transplantation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.